| Date Filed | Type | Description |
| 10/10/2023 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 06/07/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
424B2
| Form 424B2 - Prospectus [Rule 424(b)(2)]: |
| 04/27/2023 |
8-K
| Quarterly results |
| 04/14/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/14/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/27/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/27/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/27/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/22/2023 |
8-K
| Credit agreement amendment|
Docs:
|
"Form of Pre-Funded Common Stock Purchase Warrant",
"Form of Common Stock Purchase Warrant",
"Opinion of Pillsbury Winthrop Shaw Pittman LLP",
"Form of Securities Purchase Agreement, between Acer Therapeutics Inc. and the Purchaser",
"Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules NEWTON, MA - March 22, 2023 - Acer Therapeutics Inc. , a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that it has entered into a definitive agreement for the purchase and sale of 2,920,306 shares of the Company's common stock at a purchase price of $0.916 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue warrants to purchase up to 2,920,306 shares of common stock. The warrants will have an exercise price of $0.7..." |
|
| 03/22/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/17/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/16/2023 |
4
| Quartel Adrian W (Chief Medical Officer) has filed a Form 4 on Acer Therapeutics Inc.|
Txns:
| Granted 30,000 options to buy
@ $1.67, valued at
$50.1k
|
|
| 03/16/2023 |
4
| Paul Bernard H (Chief People Officer) has filed a Form 4 on Acer Therapeutics Inc.|
Txns:
| Granted 30,000 options to buy
@ $1.67, valued at
$50.1k
|
|
| 03/16/2023 |
4
| PALMIN HARRY S (CFO) has filed a Form 4 on Acer Therapeutics Inc.|
Txns:
| Granted 30,000 options to buy
@ $1.67, valued at
$50.1k
|
|
| 03/16/2023 |
4
| Klopp John Michael (Chief Technical Officer) has filed a Form 4 on Acer Therapeutics Inc.|
Txns:
| Granted 30,000 options to buy
@ $1.67, valued at
$50.1k
|
|
| 03/16/2023 |
4
| Joseph Donald (Chief Legal Officer and Secy) has filed a Form 4 on Acer Therapeutics Inc.|
Txns:
| Granted 30,000 options to buy
@ $1.67, valued at
$50.1k
|
|
| 03/16/2023 |
4
| Hayden Tanya (COO) has filed a Form 4 on Acer Therapeutics Inc.|
Txns:
| Granted 30,000 options to buy
@ $1.67, valued at
$50.1k
|
|
| 03/16/2023 |
4
| GRIFFIN MICHELLE RENEE (Director) has filed a Form 4 on Acer Therapeutics Inc.|
Txns:
| Granted 20,000 options to buy
@ $1.67, valued at
$33.4k
|
|
| 03/16/2023 |
4
| DUNN JOHN MICHAEL (Director) has filed a Form 4 on Acer Therapeutics Inc.|
Txns:
| Granted 20,000 options to buy
@ $1.67, valued at
$33.4k
|
|
| 03/16/2023 |
4
| Davis Jefferson E (Chief Business Officer) has filed a Form 4 on Acer Therapeutics Inc.|
Txns:
| Granted 30,000 options to buy
@ $1.67, valued at
$50.1k
|
|
| 03/16/2023 |
4
| ASELAGE STEVE (Director) has filed a Form 4 on Acer Therapeutics Inc.|
Txns:
| Granted 20,000 options to buy
@ $1.67, valued at
$33.4k
|
|
| 03/16/2023 |
4
| Amello Jason (Director) has filed a Form 4 on Acer Therapeutics Inc.|
Txns:
| Granted 20,000 options to buy
@ $1.67, valued at
$33.4k
|
|
| 03/15/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G/A
| Nantahala Capital Management, LLC reports a 7.5% stake in Acer Therapeutics Inc. |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/07/2023 |
424B2
| Form 424B2 - Prospectus [Rule 424(b)(2)]: |
| 02/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
|